RecruitingPhase 3NCT04799002

Topotecan and Melphalan for Retinoblastoma

Choice of Topotecan or Melphalan in Retinoblastoma Patients

Sponsor

Sun Yat-sen University

Enrollment

50 participants

Start Date

Mar 11, 2021

Study Type

INTERVENTIONAL

Conditions

Chemotherapy Effect Retinoblastoma

Summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Eligibility

Inclusion Criteria2

diagnosed as retinoblastoma
receiving eyeball-sparing treatment

Exclusion Criteria1

disease progression during follow-up

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTopotecan

Topotecan intraocular injection for chemotherapy in retinoblastoma

DRUGMelphalan

Melphalan intraocular injection for chemotherapy in retinoblastoma

Locations(1)

Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04799002

Related Trials

Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

NCT075618921 location

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT011093945 locations